128 filings
8-K
AKRO
Akero Therapeutics Inc
18 Mar 24
Unregistered Sales of Equity Securities
4:31pm
8-K
AKRO
Akero Therapeutics Inc
6 Mar 24
Entry into a Material Definitive Agreement
5:25pm
424B5
AKRO
Akero Therapeutics Inc
6 Mar 24
Prospectus supplement for primary offering
5:16pm
424B5
AKRO
Akero Therapeutics Inc
4 Mar 24
Prospectus supplement for primary offering
5:21pm
8-K
AKRO
Akero Therapeutics Inc
4 Mar 24
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
7:55am
S-8
3a7uzqlvwhb81ejld
29 Feb 24
Registration of securities for employees
4:42pm
8-K
4b9uxwunc3qs
29 Feb 24
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7:15am
8-K
zv5mxxpcogwp 2d570
18 Dec 23
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
7:08am
8-K
nhynlwitd bf4uqsq
13 Nov 23
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:15am
8-K
ffrlubb8wcv
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
b617rnwclx301kung9t
11 Aug 23
Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
6:09am
8-K
hin17xx71 uxa1ne44l
26 Jun 23
Submission of Matters to a Vote of Security Holders
4:02pm
8-K
ncfj962
5 Jun 23
Results of Operations and Financial Condition
8:05am
8-K
7l2urp4czgxl2ppr
17 May 23
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
5:01pm
424B5
ostljc0 efj884nvv
17 May 23
Prospectus supplement for primary offering
4:45pm
8-K
ti0 0u49nqwiqy
15 May 23
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
7:19am